Get the Stockscreener App
9.59
1.70%
0.16
After Hours:
9.62
0.03
+0.31%
Adicet Bio Inc stock is traded at $9.59, with a volume of 44,517.
It is up +1.70% in the last 24 hours and up +4.13% over the past month.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
See More
Previous Close:
$9.43
Open:
$9.33
24h Volume:
44,517
Relative Volume:
0.50
Market Cap:
$89.78M
Revenue:
$24.99M
Net Income/Loss:
$-108.83M
P/E Ratio:
-0.6381
EPS:
-15.0286
Net Cash Flow:
$-91.62M
1W Performance:
+5.85%
1M Performance:
+4.13%
6M Performance:
+26.68%
1Y Performance:
-15.96%
1-Day Range:
$9.261
$9.76
1-Week Range:
$8.62
$9.76
52-Week Range:
$6.01
$17.44
Adicet Bio Inc Stock (ACET) Company Profile
Name
Adicet Bio Inc
Sector
Industry
Phone
617-482-2333
Address
131 DARTMOUTH STREET, BOSTON
Compare ACET vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACET
Adicet Bio Inc
|
9.59 | 87.81M | 24.99M | -108.83M | -91.62M | -15.03 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Adicet Bio Inc Stock (ACET) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-24 | Resumed | Guggenheim | Buy |
| Sep-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-27-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-27-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Mar-31-22 | Initiated | SMBC Nikko | Outperform |
| Mar-08-22 | Initiated | Truist | Buy |
| Mar-04-22 | Initiated | Jefferies | Buy |
| May-18-21 | Initiated | BTIG Research | Buy |
| Apr-23-21 | Initiated | H.C. Wainwright | Buy |
| Apr-14-21 | Initiated | Canaccord Genuity | Buy |
| Apr-08-21 | Initiated | Guggenheim | Buy |
| Nov-04-20 | Initiated | B. Riley Securities | Buy |
| Oct-27-20 | Initiated | JMP Securities | Mkt Outperform |
| Oct-16-20 | Initiated | Wedbush | Outperform |
View All
Adicet Bio Inc Stock (ACET) Latest News
Wall Street Analysts See a 258.21% Upside in Adicet Bio (ACET): Can the Stock Really Move This High? - Yahoo Finance
Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Adicet Bio (NASDAQ:ACET) Upgraded to Strong-Buy at Jefferies Financial Group - MarketBeat
A biotech CEO will speak in New York Sept. 15. Audio will be online. - Stock Titan
Adicet Bio (NASDAQ: ACET) Advances ADI-212 Clinical Trial for mCRPC and Prepares Prula-Cel Data Release - Kalkine Media
Adicet Bio (NASDAQ: ACET) Advances ADI-212 Clinical Trial for mCRPC, Prula-cel Data Expected in September 2026 - Kalkine Media
Adicet Bio, Inc. (NASDAQ:ACET) Sees Large Drop in Short Interest - MarketBeat
Adicet Bio advances CAR-T programs and clinical pipeline - grafa.com
Adicet Bio completes prula-cel Phase 1 SLE analysis - TipRanks
The final patient visit is complete in a lupus cell-therapy study. Adicet Bio expects results from 22 patients in September. - Stock Titan
Adicet Bio grants a new hire options on 1,500 shares over four years - Stock Titan
Adicet Bio (NASDAQ:ACET) Stock Rating Lowered by Wall Street Zen - MarketBeat
Press Release Service: Adicet Bio Announces FDA Clearance of IND Application for ADI-212 - CRISPR Medicine News
Adicet Bio Gets FDA Clearance for IND for ADI-212 in prostate cancer - marketscreener.com
Adicet Bio receives FDA clearance for prostate cancer trial - Investing.com
Here's Why You Should Add ACET Stock to Your Portfolio Now - Yahoo Finance
Adicet (ACET) Trading: Adds 0.32% to Close at $9.41 in the Current Update; Key Range - vinanet.vn
ETFs Investing in Adicet Bio Inc Stocks - TradingView
Are Medical Stocks Lagging Adicet Bio (ACET) This Year? - Yahoo Finance
ACET Q2 2026 Earnings: Narrower-Than-Expected Loss of $1.99 Per Share Buoys SharesSegment Revenue Breakdown - vinanet.vn
RA Capital discloses 9.99% Adicet Bio (ACET) stake with warrant blocker - Stock Titan
Adicet Bio (ACET) - Zacks Investment Research
Adicet Bio: A Cheap Gamma Delta T-Cell Play (NASDAQ:ACET) - Seeking Alpha
Wall Street Analysts Think Adicet Bio (ACET) Could Surge 301.57%: Read This Before Placing a Bet - Zacks Investment Research
Adicet Bio (ACET) Edges Higher to $8.26 as Biotech Stock Consolidates Between Key LevelsETF Flow - Vinanet
HC Wainwright Has Strong Estimate for Adicet Bio Q3 Earnings - MarketBeat
Adicet Bio at Canaccord Genuity: lupus data drives next step By Investing.com - Investing.com Canada
Adicet Bio Eyes Key Lupus Data This Quarter for Off-the-Shelf Cell Therapy - MarketBeat
All You Need to Know About Adicet Bio (ACET) Rating Upgrade to Buy - newsbreak.com
H.C. Wainwright Maintains Adicet Bio(ACET.US) With Buy Rating, Maintains Target Price $27 - Moomoo
JonesTrading Maintains Adicet Bio(ACET.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Price to sales forward of Adicet Bio, Inc. – NASDAQ:ACET - TradingView
Adicet Bio Inc (ACET) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Press Release Service: Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates - CRISPR Medicine News
Guggenheim cuts Adicet Bio stock price target to $90 on cash position - Investing.com UK
CCORF Maintains Adicet Bio(ACET.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Adicet Bio, Inc. Stock 12‑Month Price Target Cut to $34.4, Implies 276% Upside - TradingView
ADICET BIO Q2 NET INCOME USD -21.358 MILLION - Moomoo
ADICET Bio, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Adicet Bio (NASDAQ:ACET) Posts Earnings Results, Misses Estimates By $0.30 EPS - MarketBeat
Adicet Bio Q2 net loss narrows - TradingView
Adicet Bio reports Q2 2026 net loss $21.4M; cash runway into H2 2027, clinical updates planned - TradingView
Adicet Bio, Inc. 2Q 2026: Revenue $0 Net loss $(21.4)M, EPS $(1.99) — 10-Q Summary - TradingView
ACET: Q2 2026 net loss narrowed 32% year-over-year; cash runway extends into H2 2027 - TradingView
BRIEF-Adicet Bio Q2 Basic EPS USD -1.99 - TradingView
ACET Q2'26 Earnings: EPS estimate is (1.69) USD - tradingview.com
More Than Two Decades at Johnson & Johnson: Lipocine's New Director - stocktitan.net
Adicet Bio Inc expected to post a loss of $2.03 a shareEarnings Preview - TradingView
ACET Q1 2026 Earnings: Narrower Loss Beats Estimates by 40.74% as Clinical Pipeline AdvancesConsensus Miss Rate - vinanet.vn
Adicet Bio Inc Actuals & Estimates (NASDAQ:ACET) - TradingView
Adicet Bio (NASDAQ:ACET) Share Price Passes Above 200 Day Moving AverageTime to Sell? - MarketBeat
Adicet Bio Inc Stock (ACET) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):